A strategy using NMR peptide structures of thromboxane A2 receptor as templates to construct ligand-recognition pocket of prostacyclin receptor

Cheng-Huai Ruan, Jaixin Wu, Ke-He Ruan, Cheng-Huai Ruan, Jaixin Wu, Ke-He Ruan

Abstract

Background: Prostacyclin receptor (IP) and thromboxane A2 receptor (TP) belong to rhodopsin-type G protein-coupling receptors and respectively bind to prostacyclin and thromboxane A2 derived from arachidonic acid. Recently, we have determined the extracellular loop (eLP) structures of the human TP receptor by 2-D 1H NMR spectroscopy using constrained peptides mimicking the individual eLP segments. The studies have identified the segment along with several residues in the eLP domains important to ligand recognition, as well as proposed a ligand recognition pocket for the TP receptor.

Results: The IP receptor shares a similar primary structure in the eLPs with those of the TP receptor. Forty percent residues in the second eLPs of the receptors are identical, which is the major region involved in forming the ligand recognition pocket in the TP receptor. Based on the high homology score, the eLP domains of the IP receptor were constructed by the homology modeling approach using the NMR structures of the TP eLPs as templates, and then configured to the seven transmembrane (TM) domains model constructed using the crystal structure of the bovine rhodopsin as a template. A NMR structure of iloprost was docked into the modeled IP ligand recognition pocket. After dynamic studies, the segments and residues involved in the IP ligand recognition were proposed. A key residue, Arg173 involved in the ligand recognition for the IP receptor, as predicted from the modeling, was confirmed by site-directed mutagenesis.

Conclusion: A 3-D model of the human IP receptor was constructed by homology modeling using the crystal structure of bovine rhodopsin TM domains and the NMR structures of the synthetic constrained peptides of the eLP domains of the TP receptor as templates. This strategy can be applied to molecular modeling and the prediction of ligand recognition pockets for other prostanoid receptors.

Figures

Figure 1
Figure 1
Homology modeling of the seven TM domains of human IP receptor. 3-D backbone structure of the seven TM domains of the human TP receptor were created by homology modeling using the crystal structural backbones of the TM domains of the bovine rhodopsin as templates.
Figure 2
Figure 2
Sequence alignment of the eLPs between the human IP and TP receptors. The sequences of the putative eLP domains of the human IP (45) and TP (3) receptors were aligned by a sequence alignment program in Insight II software package and manual adjustment. The identical and highly similar residues between the TP and IP are shaded. The residues in the eLP2 regions previously identified important to the ligand binding for the TP receptor (10) and their corresponding residues in the IP receptor are underlined.
Figure 3
Figure 3
The predicted backbone structures of the three eLP domains of the human IP receptor. The 3-D structural models of the eLPs were constructed by homology modeling with the NMR structures of the eLP2 (48), the eLP3 (49) and the eLP1 (unpublished data) of the human TP receptor as templates using the molecular modeling package of Insight II and Discover software packages. The conformation of the eLP2 is placed in a position with respect to the formation of a disulfide bond between the Cys92 in the eLP1 and Cys170 in the eLP2.
Figure 4
Figure 4
Configuration of the modeled 3-D backbone structures of the three IP eLP domains (Figure 4) onto the working model of the seven TM domains of the IP receptor. Before (A) and after (B) the connections of the eLP structures to the seven TMs through chemical bonds are displayed for their comparison.
Figure 5
Figure 5
Ligand docking with the eLP domains of the IP receptor. The four residues including Gln162, Leu172, Arg173 and Met174 in the IP eLP2 (eLP1, bleu color; eLP2, red color and eLP3, yellow color) in contact with iloprost were predicted by the sequence alignment (Figure 1) using the identified four residues (Val176, Leu185, Thr186 and Leu187) in the TP eLP2 contacted with SQ29,548 (10) as a template. 3-D NMR structure of the IP receptor agonist, iloprost (42) was docked into the putative ligand recognition pocket formed by the three eLPs with respect to the contacts with Leu172, Arg1173 and Met174 in the opening of the pocket. In addition, the two residues, Ala177 and Gln178 involved in contacts with iloprost predicted by NMR spectroscopic studies (42) were also used as constraints for the iloprost docking to the recognition pocket. The configuration of the model was minimized using 1,000-step energy minimization after the iloprost was docked into the pocket. The TM domains of the IP receptor are showed with green colors.
Figure 6
Figure 6
Analysis for the mutation of Arg173 to Ala residue of the recombinant human IP receptor. A). Western blot analysis. Fifty micrograms of COS-7 cells transfected with wild-type (WT) or a mutant IP receptor (R173A) cDNA was subjected to SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with rabbit anti-IP peptide antibody. (B) The ligand binding activities of wild-type and mutant TP receptor. 300 μg of the protein prepared from the COS-7 cells transfected with cDNA of the wild-type (WT) or the R173A mutant was incubated with 4 nM [3H]-iloprost (30,000 cpm) in the absence or presence of unlabeled iloprost (1 μM) in a reaction volume of 100 μl. After 1 h incubation, the reaction was stopped and the binding activity of the recombinant IP receptor was measured as described in the methods. The binding activity of wild-type receptor was considered as 100% (2,000 cpm).
Figure 7
Figure 7
Analysis of the mutation of Arg173 to Thr residue and Ser168 to Thr residue of the recombinant IP receptors. A). Western blot. B). Ligand binding activity. The methods are described in the Figure 6.
Figure 8
Figure 8
Kinetic properties of [3H] iloprost binding to the recombinant IP receptors expressed in COS-7 cells. The cell membrane protein prepared from COS-7 cells that transiently expressed the wild-type (squares), R173A mutant (circles) or R173T mutant (triangles) of the IP receptor was incubated with the increasing concentration of the [3H] iloprost.

References

    1. Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Kumley P. In: Prostaglandin and their receptor in comprehensive medicinal chemistry. Hansch C, Sammes PG, Taylor JB, Emmett JC, editor. Vol. 3. Pergamon Press, Oxford; 1990. pp. 643–714.
    1. Ushikubi F, Nakajima M, Hirata M, Okuma M, Fujiwara M, Narumiya S. Purification of the thromboxane A2/prostagiandin H2 receptor from human blood platelets. J Biol Chem. 1989;264:16496–16501.
    1. Hirata M, Hayashi Y, Ushikubi F, Yokata Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991;349:617–620. doi: 10.1038/349617a0.
    1. Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta. 1995;1259:109–120.
    1. Funk CD, Furci L, Moran N, Fitzgerald GA. Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharmacol. 1993;44:934–939.
    1. Yamamoto Y, Kamiya K, Terao S. Modeling of human thromboxane A2 receptor and analysis of the receptor-ligand interaction. J Med Chem. 1993;36:820–825. doi: 10.1021/jm00059a005.
    1. Chiang N, Kan WM, Tai HH. Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells. Arch Biochem Biophys. 1996;334:9–17. doi: 10.1006/abbi.1996.0423.
    1. Breyer RM, Audoly L. The second extracellular loop of the prostaglandin EP3 receptor is an essential determinant of ligand selectivity. J Biol Chem. 1997;272:13475–13478. doi: 10.1074/jbc.272.21.13475.
    1. Turek JW, Halmos T, Sullivan NL, Antonakis K, Le Breton GC. Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. J Biol Chem. 2002;277:16791–16797. doi: 10.1074/jbc.M105872200.
    1. So SP, Wu J, Huang G, Huang A, Li D, Ruan KH. Identification of residues important for ligand binding of thromboxane A2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J Biol Chem. 2003;278:10922–10927. doi: 10.1074/jbc.M209337200.
    1. Perlman JH, Colson AO, Jain R, Czyzewski B, Cohen LA, Osman R, Gershengorn MC. Role of the extracellular loops of the thyrotropin-releasing hormone receptor: evidence for an initial interaction with thyrotropin-releasing hormone. Biochemistry. 1997;36:15670–15676. doi: 10.1021/bi9713310.
    1. Hoffmann C, Moro S, Nicholas RA, Harden TK, Jacobson KA. The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem. 1999;274:14639–14647. doi: 10.1074/jbc.274.21.14639.
    1. Olah ME, Jacobson KA, Stiles GL. Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding: Analysis of chimeric A1/A3 adenosine receptors. J Biol Chem. 1994;269:24692–24698.
    1. Kim J, Jiang Q, Glashofer M, Yehle S, Wess J, Jacobson KA. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol. 1996;49:683–691.
    1. Zhao MM, Hwa J, Perez DM. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. Mol Pharmacol. 1996;50:1118–1126.
    1. Henderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E, Downing KH. Model for the structure of bacteriorhodopsin based on high-resolution electron cryomicroscopy. J Mol Biol. 1990;213:899–929.
    1. Gregorieff N, Ceska TA, Downing KH, Baldwin JM, Henderson R. Electron crystallographic refinement of the structure of bacteriorhodopsin. J Mol Biol. 1996;259:393–421. doi: 10.1006/jmbi.1996.0328.
    1. Edman K, Nollert P, Royant A, Belrhali H, Pebay-Peyroula E, Hajdu J, Neutze R, Landau EM. High resolution x-ray structure of an early intermediate in the bacteriorhodopsin photocycle. Nature. 1999;401:822–826. doi: 10.1038/44623.
    1. Luecke H, Schobert B, Richter HT, Cartailler JP, Lanyi JK. Structure of bacteriorhodopsin at 1.55Angstrom resolution. J Mol Biol. 1999;291:899–911. doi: 10.1006/jmbi.1999.3027.
    1. Findlay J, Eliopoulos E. Three-dimensional modeling of G protein-linked receptors. Trends Pharmacol Sci. 1990;12:492–499. doi: 10.1016/0165-6147(90)90050-I.
    1. Grotzinger J, Engels M, Jacoby E, Wollmer A, Strassburger W. A model for the C5a receptor and for its interaction with the ligand. Protein Eng. 1991;7:767–771.
    1. Hibert MF, Trumppkallmeyer S, Bruinvels A, Hoflack J. 3-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol. 1991;40:8–15.
    1. Ijzerman AP, Galen JV, Jacobson KA. Molecular modeling of adenosine receptors. I.The ligand binding site on the A1 receptor. Drug Des Discov. 1992;9:49–67.
    1. Lewell XQ. A model of the adrenergic beta-2 receptor and binding sites for agonist and antagonist. Drug Des Discov. 1992;9:29–48.
    1. Cronet P, Sander C, Vriend G. Modeling of transmembrane 7helix bundles. Protein Eng. 1993;6:59–64.
    1. Sylte I, Edvardsen O, Dahl SG. Molecular dynamics of the 5-HT1a receptor and ligands. Protein Eng. 1993;6:691–700.
    1. Zhang DQ, Weinstein H. Signal transduction by a 5-HT2 receptor – a mechanistic hypothesis from molecular-dynamics simulations of the 3-dimensional model of the receptor complexed to ligands. J Med Chem. 1993;36:934–938. doi: 10.1021/jm00059a021.
    1. Van Rhee AM, Fischer PJM, Van G, Jacobson KA. Modeling the P2y purinoceptor using rhodopsin template. Drug Des Discov. 1995;13:133–137.
    1. Pogozheva ID, Lomize AL, Mosberg HI. The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints. Biophys J. 1997;72:1963–1985.
    1. Baldwin JM. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993;12:1693–1703.
    1. Herzyk P, Hubbard RE. Combined biophysical and biochemical information confirms arrangement of transmembrane helices visible from the three-dimensional map of frog rhodopsin. J Mol Biol. 1998;281:741–754. doi: 10.1006/jmbi.1998.1981.
    1. Konvicka K, Guarnieri F, Ballesteros JA, Weinstein H. A proposed structure for transmembrane segment 7of G protein-coupled receptors incorporating an Asn-Pro/Asp-Pro motif. Biophys J. 1998;75:601–611.
    1. Attwood TK, Findlay JBC. Design of a discriminating fingerprint for G-protein-coupled receptors. Protein Eng. 1993;6:167–176.
    1. Schertler GFX, Villa C, Henderson R. Projection structure of rhodopsin. Nature. 1993;362:770–772. doi: 10.1038/362770a0.
    1. Schertler GFX, Hargrave PA. Projection structure of frog rhodopsin in two crystal forms. Proc Natl Acad Sci USA. 1995;92:11578–11582.
    1. Davies A, Schertler GFX, Gowen BE, Saibil HR. Projection structure of an invertebrate rhodopsin. J Struct Biol. 1996;117:36–44. doi: 10.1006/jsbi.1996.0067.
    1. Krebs A, Villa C, Edwards PC, Schertler GFX. Characterization of an improved two dimensional p22121 crystal from bovine rhodopsin. J Mol Biol. 1998;282:991–1003. doi: 10.1006/jmbi.1998.2070.
    1. Unger VM, Schertler GFX. Low-resolution structure of bovine rhodopsin determined by electron cryomicroscopy. Biophys J. 1995;68:1776–1786.
    1. Unger VM, Hargrave PA, Baldwin JM, Schertler GFX. Arrangement of rhodopsin transmembrane alpha-helices. Nature. 1997;389:203–206. doi: 10.1038/38316.
    1. Katsuyama M, Sugimoto Y, Namba T, Irie A, Negishi M, Narumiya S, Ichikawa A. Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett. 1994;344:74–88. doi: 10.1016/0014-5793(94)00355-6.
    1. Ruan KH, Milfeld K, Kulmacz RJ, Wu KK. Comparison of the construction of a 3-D model for human thromboxane synthase using P450 cam and BM-3 as templates: implications for the substrate binding pocket. Protein Eng. 1994;7:1345–1351.
    1. Ruan KH, Wu J, So SP, Jenkins LA. Evidence of the residues involved in ligand recognition in the second extracellular loop of the prostacyclin receptor characterized by high resolution 2D NMR techniques. Arch Biochem Biophys. 2003;418:25–33. doi: 10.1016/S0003-9861(03)00401-6.
    1. Ruan KH, Wu J, So SP, Jenkins LA, Ruan CH. NMR structure of the thromboxane A2 receptor ligand recognition pocket. Eur J Biochem. 2004;271:3006–16. doi: 10.1111/j.1432-1033.2004.04232.x.
    1. Ruan KH, So SP, Wu J, Li D, Huang A, Kung J. Solution structure of the second extracellular loop of human thromboxane A2 receptor. Biochemistry. 2001;40:275–280. doi: 10.1021/bi001867c.
    1. Wu J, So SP, Ruan KH. Solution structure of the third extracellular loop of human thromboxane A2 receptor. Arch Biochem Biophys. 2003;414:287–293. doi: 10.1016/S0003-9861(03)00192-9.
    1. Franzoni L, Nicastro G, Pertinhez TA, Tato M, Nakaie CR, Paiva AC, Schreier S, Spisni A. Structure of the C-terminal fragment 300–320 of the rat angiotensin II AT1A receptor and its relevance with respect to G-protein coupling. J Biol Chem. 1997;272:9734–9741. doi: 10.1074/jbc.272.15.9734.
    1. Anand-Srivastava MB, Sehl PD, Lowe DG. Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. J Biol Chem. 1996;271:19324–19329. doi: 10.1074/jbc.271.32.19324.
    1. Dias JA. Human follitropin heterodimerization and receptor binding structural motifs: identification and analysis by a combination of synthetic peptide and mutagenesis approaches. Mol Cell Endocrinol. 1996;125:45–54. doi: 10.1016/S0303-7207(96)03947-0.
    1. Takemoto DJ, Morrison D, Davis LC, Takemoto LJ. C-terminal peptides of rhodopsin. Determination of the optimum sequence for recognition of retinal transducin. Biochem J. 1986;235:309–312.
    1. Konig B, Arendt A, McDowell JH, Kahlert M, Hargrave PA, Hofmann KP. Three cytoplasmic loops of rhodopsin interact with transducin. Proc Natl Acad Sci USA. 1989;86:6878–6882.
    1. Okamoto T, Nishimoto I. Detection of G protein-activator regions in M4 subtype muscarinic, cholinergic, and alpha 2-adrenergic receptors based upon characteristics in primary structure. J Biol Chem. 1992;267:8342–8346.
    1. Yeagle PL, Alderfer JL, Albert AD. Three-dimensional structure of the cytoplasmic face of the G protein receptor rhodopsin. Biochemistry. 1997;36:9649. doi: 10.1021/bi970908a.
    1. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci USA. 2002;30:5982–7. doi: 10.1073/pnas.082666399.
    1. Biosym/MSI, Insight User Guide. San Diego, CA; 1995.
    1. Hatae N, Yamaoka K, Sugimoto Y, Negishi M, Ichikawa A. Augmentation of receptor-mediated adenylyl cyclase activity by Gi-coupled prostaglandin receptor subtype EP3 in a Gbetagamma subunit-independent manner. Biochem Biophys Res Commun. 2002;290:162–168. doi: 10.1006/bbrc.2001.6169.

Source: PubMed

Подписаться